HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC switch meeting

This article was originally published in The Rose Sheet

Executive Summary

FDA will consider adequacy of current structure for marketing OTC products and the agency's role in switch products at a public hearing June 28-29. The agency also seeks comments on criteria to consider in deciding on OTC availability of drugs; the classes of any Rx products that should be considered for OTC treatment; consumer understanding of issues relating to OTC drug availability; and how rational treatment decisions are affected by coexisting Rx and OTC therapies for a particular disease. The announcement is published in the Federal Register April 27
UsernamePublicRestriction

Register

RS007959

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel